CNTY-813
/ Century Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 01, 2026
CNTY-813: scalable production of allo-evasion 5.0-engineered IPSC-derived islets for off-the-shelf cell therapies
(EASD 2026)
- "Clinical-scale production of CNTY-813 generates high-purity iPSC-derived beta islets with robust endocrine function and the demonstrated ability to evade the host immune system. Preclinical data supports its potential as an off-the-shelf allogeneic functionally curative therapy for T1D."
Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • CHGA • SLC51B
1 to 1
Of
1
Go to page
1